^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BMS-986416

    i
    Other names: BMS986416, BMS 986416, ONO-7122, BMS-986416, AVID200, AVID-200, AVID 200, AVID200 DP, TGFβ receptor ectodomain-IgG Fc fusion protein
    Associations

    News

    Trials
    Company:
    BMS, Ono Pharma
    Drug class:
    TGFβ inhibitor
    Related drugs:
    Associations

    News

    Trials
    1m
    A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors (clinicaltrials.gov)
    P1, N=134, Active, not recruiting, Bristol-Myers Squibb | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy
    |
    Opdivo (nivolumab) • BMS-986416
    7ms
    A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors (clinicaltrials.gov)
    P1, N=134, Recruiting, Bristol-Myers Squibb | Trial completion date: Nov 2023 --> Jun 2028 | Trial primary completion date: Nov 2023 --> Dec 2026
    Trial completion date • Trial primary completion date • Combination therapy
    |
    Opdivo (nivolumab) • BMS-986416
    over2years
    TGFβ1 protein trap AVID200 beneficially affects hematopoiesis and bone marrow fibrosis in myelofibrosis. (PubMed, JCI Insight)
    To assess the in vivo effects of AVID200, Gata1low mice, a murine model of MF, were treated with AVID200 resulting in the reduction in bone marrow (BM) fibrosis and an increase in BM cellularity. AVID200 treatment also increased the frequency and numbers of murine progenitor cells as well as short and long term HSCs.Collectively, these data provide the rationale for TGFβ1 blockade with AVID200 as a therapeutic strategy for MF patients.
    Journal
    |
    JAK2 (Janus kinase 2) • TGFB1 (Transforming Growth Factor Beta 1) • GATA1 (GATA Binding Protein 1) • CDKN1C (Cyclin Dependent Kinase Inhibitor 1C) • TGFB2 (Transforming Growth Factor Beta 2)
    |
    JAK2 V617F
    |
    BMS-986416
    over3years
    [VIRTUAL] Rationale for and Results of a Phase I Study of the TGF-β 1/3 Inhibitor AVID200 in Subjects with Myelofibrosis: MPN-RC 118 Trial (ASH 2020)
    Clinical Trial Design: Based on these findings, a phase 1 trial of AVID200 is ongoing in INT-2/high risk MF subjects resistant or intolerant to ruxolitinib; baseline platelet count of ≥ 25 x 109/L, and grade 2/3 BMF. Furthermore, AVID200 therapy improved thrombocytopenia in MF subjects which may be due to AVID200 inhibiting the effects of TGFβ1 on normal MKpoiesis. Updated subject safety and efficacy data along with correlative data will be presented.
    Clinical • P1 data
    |
    JAK2 (Janus kinase 2) • TGFB1 (Transforming Growth Factor Beta 1)
    |
    Jakafi (ruxolitinib) • BMS-986416